Irrespective of the above, these initial studies provide “proof-of-concept” that therapeutically targeting the RANKL/RANK signaling axis may offer a new treatment modality in the clinical management of salivary gland cancers. The gene discussed is TNFRSF11A; the disease is salivary gland cancer.